InsidersTradesSigma
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
Discover the full record of transactions filed by Mehalick David, 董事长兼首席执行官. Officer active across 2 companies, notably Coeptis Therapeutics Inc.. Cumulatively, 4 filings have been recorded. Breakdown: 1 buy · 1 sell. Total volume traded: €3k. History available since 7 December 2023. The latest transaction was disclosed on 11 February 2026 (Levée d'options). Regulator: SEC (Form 4). All data is free.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
4 条申报中的 4 条
David Mehalick is the CEO and President of Coeptis Therapeutics Inc. As the leader of the company, he is responsible for setting the strategic vision and overseeing daily operations. His role is crucial in guiding the company within the biotechnology sector, ensuring innovation and growth.